Literature DB >> 16959171

Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation.

J Brazier1, I Tumur, M Holmes, M Ferriter, G Parry, K Dent-Brown, S Paisley.   

Abstract

OBJECTIVES: To summarise the available evidence on the clinical effectiveness and cost-effectiveness of psychological therapies including dialectical behaviour therapy (DBT) for borderline personality disorder (BPD). DATA SOURCES: Electronic databases were searched up to March 2005. REVIEW
METHODS: Relevant studies were assessed using standard checklists and data were abstracted by two reviewers using standardised forms. Separate economic evaluations were undertaken for six selected randomised controlled trials (RCTs). Cost-effectiveness was assessed in terms of cost per parasuicide event avoided in all six trials and cost per quality-adjusted life-year (QALY) in four of them. All results are at 2003-4 prices and for 12 months follow-up.
RESULTS: Nine RCTs and one non-RCT of moderate to poor quality were identified in the clinical effectiveness review. They provided some evidence that DBT is more effective than treatment as usual (TAU) for the treatment of chronically parasuicidal and drug-dependent borderline women; that DBT-orientated therapy is more effective than client-centred therapy (CCT) for the treatment of BPD; and that DBT is as effective as comprehensive validation therapy plus 12-Step for the treatment of opioid-dependent borderline women. There was also some evidence that partial hospitalisation is more effective than TAU in the treatment of BPD, good evidence that manual-assisted cognitive behavioural therapy (MACT) is no more effective than TAU in the treatment of BPD and some evidence that interpersonal group therapy is no more effective than individual mentalisation-based partial hospitalisation (MBT) for the treatment of BPD. However, these results should be interpreted with caution as not all studies were primarily targeted to borderline symptoms and there were considerable differences between the studies. The assessment of cost-effectiveness found a mix of results in the four trials of DBT, along with the high levels of uncertainty and the limitations in the analyses. The findings do not support the cost-effectiveness of DBT though they suggest it has the potential to be cost-effective. The results for MBT are promising, though again surrounded by a high degree of uncertainty and for MACT, the analysis suggests that the intervention is unlikely to be cost-effective.
CONCLUSIONS: The overall efficacy of psychological therapies is promising; however, at this stage the evidence is inconclusive. The cost-effectiveness of the intervention in six RCTs examined, however, does not support the cost-effectiveness of DBT although potential is suggested. There is a need for considerable research in this area. This research should involve appropriately powered head-to-head RCTs of psychological therapies; a survey of current practice and the use of the full range of services by people with BPD to inform future economic analyses; full resource-use data collected in the context of pragmatic clinical trials; psychometric assessment of the validity of the EQ-5D or other generic and condition-specific preference-based measures in BPD, and the development of a more formal cost-effectiveness model using the above data.

Entities:  

Mesh:

Year:  2006        PMID: 16959171     DOI: 10.3310/hta10350

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  17 in total

Review 1.  Mentalization-Based Treatment for Personality Disorders: Efficacy, Effectiveness, and New Developments.

Authors:  Jana Volkert; Sophie Hauschild; Svenja Taubner
Journal:  Curr Psychiatry Rep       Date:  2019-03-09       Impact factor: 5.285

2.  Dialectical behaviour therapy in adolescents for suicide prevention: systematic review of clinical-effectiveness.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-03-01

Review 3.  The association of bipolar spectrum disorders and borderline personality disorder.

Authors:  Diomidis Antoniadis; Maria Samakouri; Miltos Livaditis
Journal:  Psychiatr Q       Date:  2012-12

Review 4.  Borderline personality disorder and depression: an update.

Authors:  Maria Luca; Antonina Luca; Carmela Calandra
Journal:  Psychiatr Q       Date:  2012-09

Review 5.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

6.  Recovery in Borderline Personality Disorder (BPD): a qualitative study of service users' perspectives.

Authors:  Christina Katsakou; Stamatina Marougka; Kirsten Barnicot; Mark Savill; Hayley White; Kate Lockwood; Stefan Priebe
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

Review 7.  A systematic review of economic evaluations of treatments for borderline personality disorder.

Authors:  Christian Brettschneider; Steffi Riedel-Heller; Hans-Helmut König
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

8.  Reducing suicidal ideation: cost-effectiveness analysis of a randomized controlled trial of unguided web-based self-help.

Authors:  Bregje A J van Spijker; M Cristina Majo; Filip Smit; Annemieke van Straten; Ad J F M Kerkhof
Journal:  J Med Internet Res       Date:  2012-10-26       Impact factor: 5.428

9.  Efficacy and cost-effectiveness of an experimental short-term inpatient Dialectical Behavior Therapy (DBT) program: study protocol for a randomized controlled trial.

Authors:  Louisa M C van den Bosch; Roland Sinnaeve; Leona Hakkaart-van Roijen; Eric F van Furth
Journal:  Trials       Date:  2014-05-01       Impact factor: 2.279

10.  Health related quality of life for young people receiving dialectical behaviour therapy (DBT): a routine outcome-monitoring pilot.

Authors:  M Swales; R A B Hibbs; L Bryning; R P Hastings
Journal:  Springerplus       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.